Key result
Modified Wenyang Buxin decoction improves LVEF by ~9% vs routine therapy in chronic heart failure.
Why the study?
The effect of modified Wenyang Buxin decoction combined with routine therapy on cardiac function and serum biomarkers in chronic heart failure patients was not well established.
Does modified Wenyang Buxin decoction added to routine therapy improve cardiac function and serum biomarkers in chronic heart failure patients?
RCT (n=120)
Random number table
No
Does modified Wenyang Buxin decoction added to routine therapy improve cardiac function and serum biomarkers in chronic heart failure patients?
Modified Wenyang Buxin decoction added to routine therapy may improve cardiac function, biomarker profiles, and quality of life in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
May improve biomarkers and function as adjunct in small RCT; leaves open efficacy in larger outcome trials.
Purpose: To investigate the effect of modified Wenyang Buxin decoction and routine therapy on cardiac function and serum levels of heart-type fatty acid binding protein (H-FABP), cardiac troponin-1 (cTnI) and angiopoietin-2 (Ang-2) in chronic heart failure (CHF) patients.Methods: A total of 120 CHF patients admitted to Zhejiang Province Rongjun Hospital (from January2019 - January 2020) were selected for this study. They were randomly but equally distributed into groups A and B. All patients were given routine therapy such as diuretic treatment and detumescence, while those in group A received 150 mL of modified Wenyang Buxin decoction daily, in addition to routine therapy. At 2 months after therapy, cardiac function indices, serum H-FABP, cTnI and Ang-2 levels, hemorheology indices, traditional Chinese medicine (TCM) syndrome scores, and Chinese questionnaire of quality of life in cardiovascular patients (CQQC) scores of the two groups were evaluated.Results: After therapy, cardiac function indices, serum H-FABP, cTnI and Ang-2 levels, hemorheology indices as well as TCM syndrome score and CQQC score were significantly improved in group A, when compared with corresponding values in group B (p < 0.05).Conclusion: Modified Wenyang Buxin decoction and routine therapy improves serum biomarker levels, cardiac function and quality of life, and relieves clinical symptoms of CHF in patients. Therefore, this treatment approach may be useful in the management of CHF patients.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2022) conducted an RCT in Chronic heart failure (CHF) (n=120). Modified Wenyang Buxin decoction vs. Routine therapy was evaluated on Left ventricle ejection fraction (LVEF) (p=<0.001). Modified Wenyang Buxin decoction combined with routine therapy improved left ventricular ejection fraction compared to routine therapy alone in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: